Orlando FL-Measuring complexed PSA (cPSA) may provide improved specificity over total PSA (tPSA), according to the results of a multicenter trial. In their study, researchers from Innsbruck, Austria; Houston; New York; Cheyenne, WY; Stanford, CA; Baltimore; and Seattle compared the clinical performance of a cPSA test (Bayer Diagnostics, Tarrytown, NY) versus a standard tPSA test and PSA ratios (percent-free PSA and percent cPSA) as a first-line test for detecting prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Drug extends survival in prostate cancer with genetic mutations
December 8th 2023“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.